Origenix Technologies develops nucleic acid-based therapeutics

History:

Formed as a joint venture between Hybridon and Canadian Ventures Funds, is appears that they no longer are operating. They sold off some of their programs to Micrologix in 2002.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Northeast North America

Research Focus:
Disease Therapeutics-Research Therapeutics-Development

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: